SCHEDULE 13G/A: BlackRock Discloses 5.6% Stake in Genmab A/S Common Stock

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Genmab A/S as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 3,707,346 shares of Genmab A/S common stock.
• This represents 5.6% of the total outstanding common shares of Genmab A/S.
• BlackRock holds sole voting power over 3,341,165 shares and sole dispositive power over 3,707,346 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Genmab A/S.
• This filing is Amendment No. 5 to a previous Schedule 13G, indicating an update to BlackRock's previously reported ownership.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership, which is inherently neutral in sentiment. It does not contain positive or negative operational news about the issuer.

Positives

• BlackRock, a major institutional investor, maintains a significant stake in Genmab A/S, indicating continued investment interest.
• The shares are held in the ordinary course of business, suggesting a passive, long-term investment strategy rather than an activist one.

Future Outlook

NA

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure by a major institutional asset manager, BlackRock, indicating its passive investment stake in Genmab A/S. Such filings are common for large funds that cross ownership thresholds and reflect ongoing portfolio management rather than specific industry-wide strategic shifts.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company.

Key Dates

Keywords

BlackRock, Genmab A/S, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing